Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Iovance Biotherapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
Iovance Biotherapeutics has a total shareholder equity of $768.5M and total debt of $1,000.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are $964.3M and $195.8M respectively.
Anahtar bilgiler
0.1%
Borç/özkaynak oranı
US$1.00m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$412.54m |
| Eşitlik | US$768.54m |
| Toplam yükümlülükler | US$195.78m |
| Toplam varlıklar | US$964.32m |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Sep 06Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Aug 11
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Aug 11Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Jun 26Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Iovance Biotherapeutics: Uncertainty And Opportunity
Dec 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: IOVA's short term assets ($482.3M) exceed its short term liabilities ($93.6M).
Uzun Vadeli Yükümlülükler: IOVA's short term assets ($482.3M) exceed its long term liabilities ($102.1M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: IOVA has more cash than its total debt.
Borcun Azaltılması: IOVA's debt to equity ratio has increased from 0% to 0.1% over the past 5 years.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: IOVA has sufficient cash runway for more than a year based on its current free cash flow.
Tahmini Nakit Akışı: Insufficient data to determine if IOVA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.